Relation of JAK2 V617F allele burden and coronary calcium score in patients with essential thrombocythemia
References
- Tefferi A, Pardanani A. Myeloproliferative neoplasms: a contemporary review. JAMA Oncol 2015; 1: 97–105. doi: 10.1001/jamaoncol.2015.89
- Chuzi S, Stein BL. Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery. Leuk Lymphoma 2017; 58: 2786–2798. doi: 10.1080/10428194.2017.1312371
- Bousoik E, Montazeri Aliabadi H. “Do we know Jack” about JAK? A closer look at JAK/STAT signaling pathway. Front Oncol 2018; 8: 287. doi: 10.3389/fonc.2018.00287
- Babakhanlou R, Masarova L, Verstovsek S. A review of essential thrombocythemia and its complications. Clin Adv Hematol Oncol 2023; 21: 76–84. PMID: 36780473
- Misaka T, Kimishima Y, Yokokawa T, Ikeda K, Takeishi Y. Clonal hematopoiesis and cardiovascular diseases: role of JAK2V617F. J Cardiol 2023; 81: 3–9. doi: 10.1016/j.jjcc.2022.02.001
- Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med 2017; 377: 111–21. doi: 10.1056/NEJMoa1701719
- Anžič Drofenik A, Vrtovec M, Božič Mijovski M, Sever M, Preložnik Zupan I, Kejžar N, et al. Progression of coronary calcium burden and carotid stiffness in patients with essential thrombocythemia associated with JAK2 V617F mutation. Atherosclerosis 2020; 296: 25–31. doi: 10.1016/j.atherosclerosis.2020.01.001
- Vrtovec M, Anzic A, Preložnik Zupan I, Zaletel K, Blinc A. Carotid artery stiffness, digital endothelial function, and coronary calcium in patients with essential thrombocytosis, free of overt atherosclerotic disease. Radiol Oncol 2017; 51: 203–10. doi: 10.1515/raon-2017-0006
- Ipsogen JAK2 MutaQuant Kit Handbook. Version 1(Catalog no. 673523). Hilden, Germany: QIAGEN GmbH. 2013. p. 1–48.
- Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15: 827–32. doi: 10.1016/0735-1097(90)90282-t
- Leiva O, Gabriela Hobbs G, Ravid K, Libby P. Cardiovascular disease in myeloproliferative neoplasms. JACC CardioOncology state-of-the-art review. JACC CardioOncol 2022; 4: 166–82. doi: 10.1016/j.jaccao.2022.04.002
- Lussana F, Rambaldi A. Inflammation and myeloproliferative neoplasms. J Autoimmun 2017; 85: 58–63. doi: 10.1016/j.jaut.2017.06.010
- Genovese E, Mirabile M, Rontauroli S, Sartini S, Fantini S, Tavernari L, et al. The response to oxidative damage correlates with driver mutations and clinical outcome in patients with myelofibrosis. Antioxidants 2022; 11: 113. doi: 10.3390/antiox11010113
- Malak S, Labopin M, Saint-Martin C, Bellanne-Chantelot C, Najman A. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications. Blood Cells Mol Dis 2012; 49: 170–6. doi: 10.1016/j.bcmd.2012.06.004
- Wang W, Liu W, Fidler T, Wang Y, Tang Y, Woods B, et al. Macrophage inflammation, erythrophagocytosis, and accelerated atherosclerosis in Jak2 (V617F) mice. Circ Res 2018; 123: e35–47. doi: 10.1161/CIRCRESAHA.118.313283
- Edelmann B, Gupta N, Schnoeder TM, Oelschlegel AM, Shahzad K, Goldschmidt J, et al. JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation. J Clin Invest 2018; 128: 4359–71. doi: 10.1172/JCI90312
- Yang X, Jia J, Yu Z, Duanmu Z, He H, Chen S, et al. Inhibition of JAK2/STAT3/SOCS3 signaling attenuates atherosclerosis in rabbit. BMC Cardiovasc Disord 2020; 20: 133. doi: 10.1186/s12872-020-01391-7
- Solli CN, Chamat-Hedemand S, Elming H, Ngo A, Kjaer L, Skov V, et al. High JAK2V617F variant allele frequency is associated with coronary artery but not aortic valve calcifications in patients with Philadelphia-negative myeloproliferative neoplasms. Eur J Haematol 2023; 111: 400–6. doi: 10.1111/ejh.14019
- Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi A, Longo G, et al. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica 2008; 93: 41–8. doi: 10.3324/haematol.11653
- Kittur J, Knudson RA, Lasho TL, Finke CM, Gangat N, Wolanskyj AP, et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 2007; 109: 2279–84. doi: 10.1002/cncr.22663
- Antonioli E, Guglielmelli P, Pancrazzi A, Bogani C, Verrucci M, Ponziani V, et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005; 19: 1847–9. doi: 10.1038/sj.leu.2403902
- Barbui T, Carobbio A, Finazzi G, Vannucchi AM, Barosi G, Antonioli E, et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica 2011; 96: 315–8. doi: 10.3324/haematol.2010.031070
- Campbell PJ, Griesshammer M, Dohner K, Dohner H, Kusec R, Hasselbalch HC, et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 2006; 107: 2098–100. doi: 10.1182/blood-2005-08-3395
- Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 2007; 21: 1952–9. doi: 10.1038/sj.leu.2404854
- Wolanskyj AP, Lasho TL, Schwager SM, McClure RF, Wadleigh M, Lee SJ, et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005; 131: 208–13. doi: 10.1111/j.1365-2141.2005.05764.x
- Zhao S, Zhang X, Xu Y, Feng Y, Sheng W, Cen J, et al. Impact of JAK2V617F mutation burden on disease phenotype in chinese patients with JAK2V617F-positive polycythemia vera (PV) and essential thrombocythemia (ET). Int J Med Sci 2016; 13: 85–91. doi: 10.7150/ijms.10539
- Lee AJ, Kim SG, Nam JY, Yun J, Ryoo HM, Bae SH. Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden. Blood Res 2021; 56: 259–65. doi: 10.5045/br.2021.2021089
- Yow KS, Liu X, Chai CN, Tung ML, Yan B, Christopher D, et al. Relationship of JAK2 (V617F) allelic burden with clinicohaematological manifestations of Philadelphia-negative myeloproliferative neoplasms. Asian Pac J Cancer Prev 2020; 21: 2805–10. doi: 10.31557/APJCP.2020.21.9.2805
- Popova-Labachevska M, Panovska-Stavridis I, Eftimov A, Kapedanovska NA, Cevreska L, Ivanovski M, et al. Evaluation of the JAK2V617F mutational burden in patients with Philadelphia chromosome negative myeloproliferative neoplasms: a single-center experience. Balkan J Med Genet 2019; 22: 31–6. doi: 10.2478/bjmg-2019-0021
- Ha JS, Kim YK, Jung SI, Jung HR, Chung IS. Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms. Ann Lab Med 2012; 32: 385–91. doi: 10.3343/alm.2012.32.6.385
- Trifa AP, Bănescu C, Voina CM, Popa Ș, Török-Vistai T, Bojan AS, et al. Modest contribution of JAK2 V617F allele burden to the occurrence of major thrombosis in polycthemia vera and essential thrombocythemia. Blood Cells Mol Dis 2018; 73: 45–6. doi: 10.1016/j.bcmd.2018.09.003
- Latagliata R, Polverelli N, Tieghi A, Palumbo GA, Breccia M, Sabattini E, et al. Comparison of JAK2 V617 -positive essential thrombocythaemia and early primary myelofibrosis: the impact of mutation burden and histology. Hematol Oncol 2018; 36: 269–75. doi: 10.1002/hon.2430
- Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia treatment algorithm 2018. Blood Cancer J 2018; 8: 2. doi: 10.1038/s41408-017-0041-8
- Morris T, Stables M, Hobbs A, de Souza P, Colville-Nash P, Warner T, et al. Effects of low-dose aspirin on acute inflammatory responses in humans. J Immunol 2009; 183: 2089–96. doi: 10.4049/jimmunol.0900477
- Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood 2013; 121: 1720–8. doi: 10.1182/blood-2012-07-443770
- Birgegård G, Besses C, Griesshammer M, Gugliotta L, Harrison CN, Hamdani et al. Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study. Haematologica 2018; 103: 51–60. doi: 10.3324/haematol.2017.174672
- Cascavilla N, De Stefano V, Pane F, Pancrazzi A, Iurlo A, Gobbi M, et al. Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study. Drug Des Devel Ther 2015; 9: 2687–94. doi: 10.2147/DDDT.S79576
- Antonioli E, Carobbio A, Pieri L, Pancrazzi A, Guglielmelli P, Delaini F, et al. Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. Haematologica 2010; 95: 1435–8. doi: 10.3324/haematol.2009.021444
- Zalcberg IR, Ayres-Silva J, de Azevedo AM, Solza C, Daumas A, Bonamino M. Hydroxyurea dose impacts hematologic parameters in polycythemia vera and essential thrombocythemia but does not appreciably affect JAK2-V617F allele burden. Haematologica 2011; 96: e18–20. doi: 10.3324/haematol.2010.037846
- Quintás-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009; 27: 5418–24. doi: 10.1200/JCO.2009.23.6075
- Quintás-Cardama A, Abdel-Wahab O, Manshouri T, Kilpivaara O, Cortes J, Roupie AL, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood 2013; 122: 893–901. doi: 10.1182/blood-2012-07-442012
- Verger E, Cassinat B, Chauveau A, Dosquet C, Giraudier S, Schlageter MH, et al. Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations. Blood 2015; 126: 2585–91. doi: 10.1182/blood-2015-07-659060
- Deininger M, Radich J, Burn TC, Huber R, Paranagama D, Verstovsek S. The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. Blood 2015; 126: 1551–4. doi: 10.1182/blood-2015-03-635235
- Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rumi E, Gattoni E, et al. Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. Blood 2017; 130: 1768–71. doi: 10.1182/blood-2017-02-765032
Language: English
Page range: 565 - 572
Submitted on: Mar 24, 2024
Accepted on: Jun 1, 2024
Published on: Oct 4, 2024
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2024 Ajda Drofenik, Ales Blinc, Mojca Bozic Mijovski, Tadej Pajic, Matjaz Vrtovec, Matjaz Sever, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.